BRAF and central nervous system neoplasm: In the field of pediatric CNS tumors, important progress has been made in molecular characterization, including the identification of critical pathway changes such as the ones that occur due to BRAF mutations, and in finding drugs both capable of passing through the BBB and exceeding the resistance capacity of CNS tumors.